modelPropacetamol
Extends from Pharmacolibrary.Drugs.ATC.N.N02BE05.
Information
| name: | Propacetamol | |
| ATC code: | N02BE05 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 2000 | mg |
| volume of distribution: | 0.95 | L |
| clearance: | 5.1 | mL/min/kg |
| other parameters in model implementation | ||
Propacetamol is a prodrug of paracetamol (acetaminophen), designed for intravenous use to provide analgesic and antipyretic effects. It is hydrolyzed rapidly to paracetamol in the body. Propacetamol was used primarily in hospital settings, especially when oral or rectal administration was not feasible. It is not widely used today, having been largely replaced by intravenous formulations of paracetamol itself.
Pharmacokinetics
Healthy adult subjects, after single intravenous dose of propacetamol (converted to paracetamol PK parameters, as propacetamol itself is rapidly hydrolyzed).
References
Anderson, BJ, et al., & Boccard, E (2005). Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. Paediatric anaesthesia 15(4) 282–292. DOI:10.1111/j.1460-9592.2005.01455.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/15787918
Prins, SA, et al., & Mathot, RA (2008). Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. Paediatric anaesthesia 18(7) 582–592. DOI:10.1111/j.1460-9592.2008.02619.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/18482233
Allegaert, K, et al., & Tibboel, D (2004). Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. European journal of clinical pharmacology 60(3) 191–197. DOI:10.1007/s00228-004-0756-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/15071761
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)